Alzprotect: AlzProtect on Track for a Phase 2 Entry in 2019 for its Drug Candidate AZP2006
LILLE France February 20 2019 B3C newswire AlzProtect a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease and Progressive Supranuclear Palsy PSP announced today the successful completion of the latest...
Read full article »
Alzprotect is a France-based biopharmaceutical company that develops and commercializes therapeutics for the treatment of neurodegenerative diseases.
Read more